Safety and Effectiveness of Giroctocogene Fitelparvovec or Fidanacogene Elaparvovec in Patients With Hemophilia A or B Respectively
Launched by PFIZER · Oct 3, 2022
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at the long-term safety and effectiveness of two treatments, giroctocogene fitelparvovec and fidanacogene elaparvovec, for men with hemophilia A and B, respectively. If you or someone you know has been part of an earlier Pfizer clinical trial and received one of these treatments, you might be eligible to join this study. The goal is to gather more information about how well these treatments work over time.
Participants in this trial will continue to receive standard care while their health is monitored. The study is currently recruiting men aged 65 to 74 who have already received one of the investigational treatments. There are no additional exclusion criteria, which means if you meet the inclusion criteria, you can participate. This trial is important because it aims to provide more insights into managing hemophilia, helping to improve treatment options for patients in the future.
Gender
MALE
Eligibility criteria
- Inclusion Criteria:
- • -Only participants who received investigational giroctocogene fitelparvovec or fidanacogene eleparvovec and were enrolled in a Pfizer-sponsored study (C0371002, C0371003, C0371005, C3731001, C3731003) are eligible.
- Exclusion Criteria:
- • -None
About Pfizer
Pfizer Inc. is a global leader in biopharmaceutical innovation, dedicated to discovering, developing, and delivering advanced therapies that enhance patient outcomes across a wide range of medical conditions. With a rich history of scientific research and a commitment to quality, Pfizer focuses on areas such as oncology, immunology, cardiology, and rare diseases. The company leverages cutting-edge technology and collaborates with healthcare professionals, regulatory bodies, and academic institutions to conduct rigorous clinical trials that ensure the safety and efficacy of its products. Pfizer's mission is to bring breakthroughs that change patients' lives, exemplifying its commitment to health and wellness worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Sacramento, California, United States
Camperdown, New South Wales, Australia
Tampa, Florida, United States
Madison, Mississippi, United States
Sacramento, California, United States
Sacramento, California, United States
Seattle, Washington, United States
Sacramento, California, United States
İzmir, İ̇zmir, Turkey
San Francisco, California, United States
İzmir, , Turkey
Philadelphia, Pennsylvania, United States
Patients applied
Trial Officials
Pfizer CT.gov Call Center
Study Director
Pfizer
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials